Enterprise Value

489.3M

Cash

138.5M

Avg Qtr Burn

-41.1M

Short % of Float

19.12%

Insider Ownership

0.51%

Institutional Own.

85.75%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nexletol (bempedoic acid) Details
Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia

Approved

Quarterly sales

Nexlizet (bempedoic acid and ezetimibe) Details
ASCVD (atherosclerotic cardiovascular disease) and HeFH (hypercholesterolemia)

Approved

Quarterly sales

Nexletol (bempedoic acid) Details
Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia, Cardiovascular risk reduction

sNDA

Acceptance for review

sNDA

Acceptance for review